Table 1.
Baseline characteristics of the participants.
| Total (n = 26) | ||
|---|---|---|
| Female, n (%) | 17 | 65.38% |
| Age (mean, SD), years | 42.37 | 9.40 |
| Age at onset of epilepsy (mean, SD), years | 29.92 | 9.32 |
| Type of seizure, n (%) | FIAS | 6 (23.07%) |
| FIAS and FAS | 12 (46.15%) | |
| FIAS and FBTCS | 8 (30.77%) | |
| Negative MRI abnormality, n (%) | 15 (57.70%) | |
| Epilepsy syndrome, n (%) | Temporal lobe epilepsy | 15 (57.70%) |
| Extratemporal lobe epilepsy | 11 (42.30%) | |
| Side of EEG focus, n (%) | Left/right | 10/5 (38.46%/19.23%) |
| Bilateral | 5 (19.23%) | |
| Unknown | 6 (23.08%) | |
| Patients with ≥3 AEDs,n (%) | 18 (69.23%) | |
| Concomitant AEDs, n (%) | Levetiracetam | 14 (53.84%) |
| Valproate | 11 (42.31%) | |
| Perampanel | 11 (42.31%) | |
| Clobazam | 9 (34.62%) | |
| Topiramate | 8 (30.77%) | |
| Lamotrigine | 8 (30.77%) | |
| Clonazepam | 5 (19.23%) | |
| Zonisamide | 4 (15.38%) | |
| Carbamazepine | 4 (15.38%) | |
| Vigabatrin | 4 (15.38%) | |
| Phenytoin | 2 (7.69%) | |
| Oxcarbazepine | 1 (3.85%) |
AED, antiepileptic drug; FIAS, focal impaired awareness seizure; FAS, focal awareness seizure; FBTCS, focal to bilateral tonic-clonic seizure; EEG, electroencephalography.